Patient Satisfaction With Tildrakizumab Treatment in a Phase 4 Real-World Study of Tildrakizumab in Patients With Moderate-to-Severe Plaque Psoriasis. J of Skin 2023, 7 (2), s134. https://doi.org/10.25251/skin.7.supp.134.